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Abstract  
We quantified the probability of developing symptoms (respiratory or fever ≥37.5 °C) and critical 
disease (requiring intensive care or resulting in death) of SARS-CoV-2 positive subjects. 4,326 
contacts of SARS-CoV-2 index cases detected in Lombardy, Italy were analyzed, and positive subjects 
were ascertained via nasal swabs and serological assays. 69.1% of all infected individuals aged less 
than 60 years did not develop symptoms (95% confidence interval: 66.7-71.4%). The risk of 
symptoms increased with age. 6.9% of infected subjects older than 60 years had critical disease, with 
males at significantly higher risk. 
 
Main  
 
Quantifying the proportion of SARS-CoV-2 infections that do not show recognizable symptoms is still 
an important missing piece in the puzzle of the ongoing pandemic [1-3]. The role of asymptomatic 
carriers in transmission is still largely uncertain [4], but episodes of transmission from symptom-free 
positive subjects have been documented [3,5,6]. Because asymptomatic infections are easily missed 
by surveillance systems, they can reduce the effectiveness of “test, trace and isolate” strategies in 
keeping transmission under control and preventing the emergence of local outbreaks [7,8]. Of 
particular relevance is the topic of transmission of infection by children, given that they are much 
less likely to experience disease [1,9] and less susceptible to infection than adults and the elderly 
[10]. Age-specific estimates on the absolute probability of developing symptoms upon infection are 
still sparse. Similarly, robust estimates of the risk of critical disease (i.e., cases requiring intensive 
care) upon infection are needed for assessing future scenarios of SARS-CoV-2 spread in terms of 
their potential healthcare burden [1,11].  
 
In this study, we analyze clinical observations of laboratory confirmed SARS-CoV-2 infections in 
Lombardy, Italy, to estimate the probability of developing symptoms and experiencing critical 
disease given SARS-CoV-2 infection, at different ages.  
 
Between February and April 2020, local health authorities (ATS) in Lombardy implemented contact 
tracing activities to investigate the history of exposure of 64,252 close contacts of 21,410 COVID-19 
cases. Cases were ascertained by using a real-time reverse transcription polymerase chain reaction 
(RT-PCR) assay targeting different genes of SARS-CoV-2 [12,13]. Close contacts of cases were defined 
as persons living in the same household of a case or who engaged face-to-face with a case within a 
distance of 2 meters for more than 15 minutes during the exposure period. The exposure period was 
initially defined as the time interval ranging from 14 days before to 14 days after the date of 
symptom onset of the index case. After March 20, the period was shortened, ranging from 2 days 
before to 14 days after the symptom onset of the index case [14]. In addition, Lombardy initiated a 
serological survey on April 16, 2020, aimed at detecting IgG neutralizing antibodies against S1/S2 
antigens of SARS-CoV-2 of all contacts of the identified index cases [15]. We use preliminary results 
from the serological survey to integrate the diagnoses of SARS-CoV-2 infection in a subset of the 
traced contacts. 
 
In particular, we selected 2,767 clusters (i.e. groups of contacts associated with an index case) where 
all contacts were tested against SARS-CoV-2 infection either via nasal swabs during follow-up of 
contact tracing activities or within the serological survey, for an overall sample of 4,326 close 
contacts (median age: 51; IQR: 29-62; 55.0% females). Subjects were defined positive to SARS CoV-2 
infections if they had at least one laboratory confirmation (either via RT-PCR or serological assay), 
irrespective of clinical signs. Symptomatic cases were defined as infected subjects showing upper or 
lower respiratory tract symptoms (e.g. cough, shortness of breath), or fever ≥37.5 °C. Critical cases 
were defined as patients either admitted to an intensive care unit or deceased with a diagnosis of 
SARS-CoV-2 infection.  
 
Among the selected 4,326 close contacts (i.e., excluding index cases), 2,351 (54%) had been infected 
(median age: 54; IQR 33-65; 55.7% females). Of these, 1,675 infections (71%) were identified by the 
serological assay, and 676 (28%) by the RT-PCR.  
 
Of the 2,351 confirmed SARS-CoV-2 infections, 849 (36.1%) were symptomatic. Data stratified by 
sex, age and testing procedure are displayed in Table 1. The probability of developing symptoms 
increased with age, ranging from 18.6% (95%CI, 14.2-23.6%) among infected individuals aged less 
than 20 years to 66.9% (95%CI, 58.6-74.5%) for subjects aged 80 years or more. Asymptomatic 
infections represented 69.1% (95%CI, 66.7-71.4%) of all infections detected in individuals younger 
than 60 years of age. The same quantitative trend was observed in an additional analysis where we 
considered all of the 6,041 infections detected so far by the ongoing analysis of the contact tracing 
records (12,316 subjects tested over a total of 64,252 contacts), thus including also clusters for 
which test results are not available for all individuals (Figure S1A). 
68 (2.9%) cases were critical (Tab. 1). Critical care was required for less than 1% of infections 
occurred under 40 years of age (mean 0.60%; 95%CI: 0. 27-1.13%), in striking contrast with the 
corresponding proportion among cases above 60 years (6.9%, 95%CI 5.3-8.9%). Male sex was 
associated with a higher risk of critical disease. The proportion of symptomatic and critical cases 
among infected males and females are shown in Figure 1.  
To test for possible cluster specific effects, we explored the relative risk (RR) of developing 
symptoms and critical disease in five 20-years-age groups using a generalized linear mixed-effects 
model (GLMM with logit link and cluster-specific random effects). The model included as covariates 
the individual’s age group and gender, a binary variable indicating whether the cluster’s index case 
was symptomatic or not, and the number of symptomatic contacts in the cluster. A strong age 
dependency in the risk of symptomatic and critical infection was found, in agreement with the main 
analysis (Figure S1B). SARS-CoV-2 positive individuals older than 60 years of age showed a 
significantly higher risk of developing symptoms compared to all younger age groups, while 
infections under 20 years of age resulted at a significantly lower risk of developing symptoms 
compared to older infections (Tukey test: p -value<0.001, Figure S1C). No significant differences 
between females and males were found in the risk of developing symptoms given the infection.  
However, females resulted 53.5% less likely to experience critical disease (95%CI 23.9-72.0).  Similar 
results were obtained in a sensitivity analysis where we considered all of the 6,041 infections 
detected in the contact tracing records (12,316 subjects tested over a total of 64,252 contacts). 
The contribution of asymptomatic infections to transmission of SARS-CoV-2 is still poorly quantified 
[2,5,16,17]; similar viral loads were found in symptomatic and asymptomatic cases [12,16] and 
infections caused by asymptomatic subjects were documented [5]. In our sample, the large majority 
of infections (Table 1) were detected retrospectively via serological testing, and of these, only one in 
eight showed recognizable symptoms. This result highlights the intrinsic difficulties in the detection 
of infections during surveillance of cases.  
 
Estimates of the proportion of SARS-CoV-2 asymptomatic infections published so far are highly 
variable, ranging from 17% to 87% [2,5,16,17], and depend on what symptoms are included in the 
definition and when they were ascertained. Here, we use the definition of any respiratory symptoms 
or the presence of fever above 37.5 °C; cases were followed up for symptoms throughout the study 
period. The proportion of asymptomatic infections found in our data is in line with recent modeling 
estimates [17] and published medical literature [5,16].  
The selected sample in our study consists of individuals identified during contact tracing, which may 
not necessarily represent the general population. However, this design has the advantage of 
assessing symptoms during active tracing and monitoring of contacts, thereby reducing the 
possibility of recall bias for individuals identified as positive through serological surveys. In addition, 
the age distribution of our sample was fairly similar to that of the Italian population. The imperfect 
sensitivity and specificity of the assays used to confirm infection [15,18] should be kept into account 
when interpreting the results of this analysis; these parameters also change with the time after 
infection at which the biological sample is collected. All individuals who tested negative to RT-PCR in 
our sample were tested for IgG serology more than 1 month after their exposure to their cluster 
index case, thus false negatives due to delays in seroconversion can be excluded. 
 
Our estimates of the age-specific probability of developing symptoms given infection can help 
separating the contribution of heterogeneous risks of infection [10] and disease [9] by age to the 
observed age distribution of cases, shedding new light on the epidemiology of COVID-19. The 
quantification of the risk of critical disease upon infection can inform estimates from transmission 
models and help ensure the sustainability of health system in terms of supplies, human resources, 
equipment and beds required at different intensities of care. 
 
Figure 1. Estimated percentage of critical and symptomatic infections in males and females across different 
age-groups. Horizontal lines represent 95% confidence intervals computed by exact binomial tests. 
 Subjects Positive to SARS-CoV-2 infection 
Symptomatic infections Critical patients 
mean 95% CI mean 95% CI 
Gender       
    Male 1,946 1,041  360/1041 (34.58%) 31.69-37.56 % 39/1041 (3.74%)  2.68-5.09 % 
    Female 2,380 1,310 489/1310 (37.33%)  34.70-40.01% 29/1310 (2.21%) 1.49-3.16 % 
Age       
    0-19y 563 280 52/280 (18.57%) 14.19-23.63 % 0/280 ( 0%)  0-1.31 % 
    20-39y 919 430 113/430 (26.28%) 22.18-30.71 % 2/430 (0.47%)  0.06-1.67 % 
    40-59y 1,545 792 299/792 (37.75%) 34.36-41.23 % 7/792 (0.88%)  0.36-1.81 % 
    60-79y 1,079 704 288/704 (40.91%) 37.25-44.64 % 32/704 (4.55%)  3.13-6.36 % 
    80+ 220 145 97/145 (66.90%) 58.60-74.48 % 27/145 (18.62%) 12.64-25.92 % 
Confirmation       
    IgG serology 2,893 1,675* 205/1675 (12.24%) 10.71-13.90 % 1/1675 (0.05%)  0-0.33% 
    RT-PCR 1,433 676 644/676 (95.27%) 93.38-96.74 % 67/676 (9.91%) 7.76-12.42% 
Total 4,326 2,351 849/2351 (36.11%) 34.17-38.09 % 68/2351 (2.89%) 2.25-3.65  
*42 confirmed also by RT-PCR 
Table 1. Sample description and estimates by sex, age group and testing procedure. 
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Figure S1. A) Comparison of the estimates obtained using all the clusters with those obtained when 
limiting attention only to infections occurred in clusters of cases contacts who were all tested 
against SARS-CoV-2 infection (vertical lines show the 95%CI). B) Relative risks (RR) of developing 
symptoms by age group (with the last age group, 80+, as reference) estimated employing a 
generalized linear mixed-effects model (GLMM) with logit link (shaded area shows 95%CI). The RR is 
higher for positive contacts with a symptomatic index case (p-value=0.005) and increases with the 
number of symptomatic infections occurred in the cluster (p-value<0.001). C) Results of Tukey post 
hoc test comparing the RRs across different age classes.  
Methods  
Sources of data 
Soon after the detection of first locally acquired infection in the Lombardy region of Italy on February 20, 2020, 
national and regional health authorities introduced coordinated interventions to control the epidemic spread. 
Local health authorities of Lombardy set up a surveillance system to detect local transmission of SARS-CoV-2 
by extensive testing, to isolate COVID-19 cases, and to identify and quarantine contacts of positive subjects. 
 
On April 16, the Lombardy Region initiated a large-scale serological screening of subjects quarantined for 
COVID-19 to evaluate the prevalence of the infection in this group. The data analyzed in this paper were 
obtained by building a database that combines the information collected during the contact tracing activities 
conducted between February and April 2020 by the Lombardy healthcare agencies, with the Lombardy linelist 
of COVID-19 patients and the initial test results obtained through the serological survey currently ongoing in 
the region. The database provides, among other details, information on the gender and the age of cases and 
case contacts, the results of PCR tests and serological tests (if any), the outcome of patients, and whether they 
were admitted to an intensive care unit. 
 
The identification and monitoring of close case contacts was performed by regional healthcare agencies, 
through standardized epidemiological investigations of positive cases (or of their relatives) to determine the 
history of individuals’ exposure. The exposure period was initially defined as the interval time ranging from 14 
days before to 14 days after the symptom onset of the index case. After March 20, the time period was 
reduced to from 2 days before to 14 days after the symptom onset of the index case [14]. 
 
According to criteria defined by the European Centre for Disease Prevention and Control (ECDC), suspected 
COVID-19 cases were identified as:  
1. patients with acute respiratory tract infection OR sudden onset of at least one of the following: 
cough, fever, shortness of breath AND with no other aetiology that fully explains the clinical 
presentation AND at least one of these other conditions: a history of travel to or residence in China, 
OR patient is a health care worker who has been working in an environment where severe acute 
respiratory infections of unknown etiology are being cared for;  
2. OR patients with any acute respiratory illness AND at least one of these other conditions: having been 
in close contact with a confirmed or probable COVID-19 case in the last 14 days prior to onset of 
symptoms, OR having visited or worked in a live animal market in Wuhan, Hubei Province, China in 
the last 14 days prior to onset of symptoms, OR having worked or attended a health care facility in 
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the last 14 days prior to onset of symptoms where patients with hospital- associated COVID-19 have 
been reported.  
Probable cases were defined as suspect cases for whom testing for virus causing COVID-19 was positive with a 
specific real-time RT PCR assay detecting the SARS-CoV-2 virus responsible for the COVID-19 (according to the 
test results reported by the laboratory) OR for whom testing inconclusive. Confirmed cases were defined as 
persons with laboratory confirmation of virus causing of SARS-CoV-2 infection, irrespective of clinical signs and 
symptoms. The Lombardy linelist of patients used to build the database analyzed here consists in all confirmed 
COVID-19 cases detected until June 8, 2020. 
 
A close case contact was defined as a person living in the same household as a COVID-19 confirmed case, a 
person having had face-to-face interaction with a COVID-19 confirmed case within 2 meters and for more than 
15 minutes; a person who was in a closed environment (e.g. classroom, meeting room, hospital waiting room) 
with a COVID-19 confirmed case at a distance of less than 2 meters for more than 15 minutes; a healthcare 
worker or other person providing direct care for a COVID-19 confirmed case, or laboratory workers handling 
specimens from a COVID-19 confirmed case without recommended personal protective equipment (PPE) or 
with a possible breach of PPE; a contact in an aircraft sitting within two seats (in any direction) of a COVID-19 
confirmed case, travel companions or persons providing care, and crew members serving in the section of the 
aircraft where the index case was seated (passengers seated in the entire section or all passengers on the 
aircraft were considered close contacts of a confirmed case when severity of symptoms or movement of the 
case indicate more extensive exposure). Close case contacts were initially considered as contacts occurred 
between 14 days before and 14 days after the onset of symptoms in the case under consideration. After 
March 20, close case contacts were defined as contacts occurred between 2 days before and 14 days after the 
case symptom onset [14]. Clusters of contacts were defined as the set contacts identified by the contact 
tracing triggered by a positive index case.  Contact data used to build the analyzed database consist of records 
collected between February 21 and April 16, 2020. Contact data collected after April 16, 2020 were excluded 
to avoid biases caused by reporting delays, delays between exposure and symptom onset, and in 
seroconversion of positive individuals. 
 
According to the WHO recommendations, nasal swabs (UTM viral transport ®, Copan Italia S.p.a) from all 
suspected cases were tested with at least two real-time RT PCR assays targeting different genes (E and RdRp) 
of SARS-CoV-2. In addition, a novel quantitative real-time RT PCR targeting an additional SARS-CoV-2 gene (M) 
was developed (details provided upon request). From February 21 to February 25, all suspected cases and 
asymptomatic contacts were tested. From February 26 onward, testing was applied only to symptomatic 
patients. From March 20, positivity to the nasal swab was also granted for tests that sought a single gene. 
Doubtful swabs were repeated to reach the diagnosis. 
 
Serological screening of subjects quarantined for COVID-19 included both symptomatic and asymptomatic 
case contacts identified through an epidemiological investigation without history of a swab for SARS-CoV-2. 
The test used to detect SARS-CoV-2 IgG antibodies is the LIAISON® SARS-CoV-2 test. The LIAISON® SARS-CoV-2 
test employs magnetic beads coated with S1 & S2 antigens. The antigens used in the tests are expressed in 
human cells to achieve proper folding, oligomer formation, and glycosylation, providing material similar to the 
native spikes. This strategy ensures that the antigen-antibody complex forms with the required specificity. The 
S1 and S2 proteins are both targets to neutralizing antibodies. The test provides the detection of IgG 
antibodies against S1/S2 antigens of SARS-CoV-2 and the detection of Neutralizing antibodies with 97,8% 
negative agreement and 94.4% positive agreement to Plaque Reduction Neutralization Test (PRNT). A negative 
result (<12 AU/mL) indicates the absence or a very low level of IgG antibodies directed against the virus, this 
occurs in the absence of infection or during the incubation period or in the early stages of the disease. A 
doubtful result (12-15 AU/mL) can be interpreted as both a false positive or a false negative and suggests 
repeating the exam after a week. A positive result (>15 AU/mL) indicates the presence of IgG antibodies and 
must be interpreted in association with the clinical outcomes and the possible search for the viral genome on 
the nasopharyngeal swab. Clusters with case contacts with doubtful results were excluded by the proposed 
analysis. 
 
The performed analysis is based on all serological test results obtained as of May 25, 2020.  
 
Statistical analysis  
Contact tracing data were combined with test and clinical outcomes of close contacts associated with each 
primary infector and used to estimate the absolute probability of relative risk of infection and of developing 
symptoms by age. We categorized contacts in five 20-years-age groups (0-19 years, 20-39 years, 40-59 years, 
60-79 years, 80+ years). Probabilities stratified by age and gender were defined as the proportion of 
symptomatic infected individuals and critical patients among the total number of infected individuals. Exact 
binomial test was applied to compute confidence intervals for different considered strata. 
 
We applied a logistic regression model where the clinical outcome of positive close contacts is considered as 
the response variable and using the following covariates: 
1) age group (of the contact); 
2) gender (of the contact); 
3) a binary variable defining whether the index case in the cluster was symptomatic or not; 
4) the number of symptomatic individuals in the cluster. 
 
Risk ratios of experiencing symptoms were computed given the covariates. Resulting means were compared 
by Tukey post hoc test. Specifically, to account for the clustering in the binary data, we applied a generalized 
linear mixed-effects model (GLMM) with logit link specified as follows: 
 𝑚(𝜇!") = 	𝛼 + 𝛽#𝐴"! + 𝛽$𝐺"! + 𝛽%𝑃"! + 𝛽&𝑁"! + 𝑢" 
 
where 𝑚 is the logit link function, 𝛼 is the intercept, 𝐴!" , 𝐺!" , 𝑃"!	 and 𝑁"! denote respectively the fixed effects 
of age group an individual 𝑖 belongs to, the gender of the contact, a binary variable indicating whether the 
exposure took place in a cluster with a symptomatic index case, and the number of symptomatic infections in 
the cluster; 𝑢" is the cluster-specific random effects and 𝜇!" = 𝐸(𝑌"!|𝑢") is the mean of the response variable 𝑌"! for a given value of the random effects. The statistical analysis was performed with R (version 3.6).  
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